ArticleDrug design, development and therapy2025
Mechanisms of Microctis Folium in Hyperlipidemia: Integrating Serum Pharmacochemistry, Network Pharmacology, and Transcriptomics.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of Hypolipidemic Constituents fromPharmaceuticals (Basel, Switzerland) · 2026Article
- Anti-Hepatocarcinoma Activity and Mechanism of Isosendanin and Its Novel Structural Analogues Isolated from the Bark ofAntioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Microctis Folium (MF), a traditional Chinese medicine (TCM), has shown promising effects in treating hyperlipidemia (HLP), yet its active constituents and mechanisms remain largely unclear. Purpose: This study aimed to systematically elucidate the lipid-lowering effects of MF on high-fat diet (HFD)-induced HLP and identify its pharmacodynamic material basis and molecular mechanism through an integrated multi-omics strategy. Methods: We developed a UPLC-QTOF-MS/MS method to identify the chemical constituents of MF and the compounds absorbed in rat serum after oral administration of MF. Network pharmacology, molecular docking, and experimental validation were utilized to explore the potential mechanism of MF for the treatment of HLP. Results: UPLC-QTOF-MS/MS identified 51 chemical compounds in MF and established their material basis. Analysis of serum samples after administration of MF identified 24 enriched compounds as potential active compounds and 597 corresponding prospective targets. Overlaying these compounds with 396 HLP-related genes revealed 101 potential core genes, mainly including AKT1, PTGS2, EGFR, mTOR, and NF-κB. Network pharmacology and transcriptomic analyses indicated that MF regulates key pathways in HLP, notably the PI3K/AKT, mTOR, and NF-κB pathways. Molecular docking further validated the binding affinities of MF key compounds (rutin and isovitexin) to AKT1, mTOR, and NF-κB. In vivo studies confirmed MF's lipid-lowering effects of MF in alleviating HFD-induced lipid accumulation. Compared to the HFD group, MF treatment significantly reduced serum triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) levels while increasing high-density lipoprotein cholesterol (HDL-C) levels. Finally, in vivo experiments confirmed the pivotal role of these pathways in the therapeutic effects of MF on HLP. Conclusion: The comprehensive approach adopted in this study reveals the molecular mechanism of MF for the treatment of HFD-induced HLP, lays an important foundation for elucidating the pharmacological and material basis of the therapeutic effects of MF, and highlights the value of multi-omics integration in TCM research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.